Us Infectious Respiratory Disease Diagnostics Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The North America infectious respiratory disease diagnostics market sits within the broader infectious disease diagnostics landscape, which was valued at approximately $8.98 billion in 2025 and is projected to reach $15.39 billion by 2033 at a 6.9% CAGR. The global infectious respiratory disease diagnostics market is similarly sized at approximately $12.6 billion in 2025, expected to grow to $15.7 billion by 2033 at a 2.9% CAGR. The United States constitutes the dominant share of the North American market, with the US respiratory infectious disease diagnostics segment alone projected at $3.5 billion in 2024 rising to $7.2 billion by 2034 at a 7.5% CAGR.

• •North America infectious disease diagnostics market: ~$8.98B (2025) → ~$15.39B (2033) at 6.9% CAGR
• •Global infectious respiratory disease diagnostics: ~$12.6B (2025) → ~$15.7B (2033) at 2.9% CAGR
• •US respiratory infectious disease diagnostics alone: ~$3.5B (2024) → ~$7.2B (2034) at 7.5% CAGR

Robust growth is underpinned by the recurring burden of seasonal respiratory epidemics, an aging population more susceptible to severe infections, and sustained institutional investment in pandemic-preparedness infrastructure developed during the COVID-19 period. The clinical preference for rapid, accurate pathogen identification over empirical treatment, driven by antibiotic stewardship programs, has accelerated adoption of molecular and multiplex panel technologies. Simultaneously, the shift toward decentralized care models and the expanding availability of over-the-counter and at-home testing are broadening the addressable market beyond traditional hospital and reference laboratory channels.

• •Recurring seasonal epidemics (influenza, RSV, COVID-19 variants) drive consistent, high-volume recurring demand
• •Antibiotic stewardship programs incentivize precise pathogen ID, accelerating molecular diagnostic adoption
• •Decentralization and at-home/OTC testing models expand market reach beyond hospital and lab settings

Molecular diagnostics, including isothermal amplification, real-time PCR, and next-generation sequencing platforms, represents the fastest-growing technology segment, valued for its high sensitivity, multiplexing capability, and shortened turnaround times. Immunoassays and rapid antigen tests retain a substantial share, particularly in point-of-care and mass-screening applications. By geography, the United States accounts for the overwhelming majority of North American market value, reflecting its larger patient population, more extensively deployed clinical laboratory infrastructure, and higher per-capita healthcare spending. Canada and Mexico represent smaller but growing sub-markets driven by expanding diagnostic access and improving healthcare coverage.

• •Molecular diagnostics (PCR, isothermal, NGS) leads growth; immunoassays and rapid antigen tests retain strong POC share
• •United States dominates North American market, driven by large population and advanced clinical laboratory infrastructure
• •Canada and Mexico are growing sub-markets, supported by expanding access and improving healthcare coverage

Who are the notable companies in the industry?

## Competitive Landscape The U.S. infectious respiratory disease diagnostics market exhibits moderate to high fragmentation, populated by large integrated in vitro diagnostics manufacturers alongside specialized producers of molecular and point-of-care respiratory platforms. **bioMérieux** is recognized as a leader in syndromic infectious disease diagnostics and multiplex respiratory pathogen testing. **Roche** operates as a global molecular diagnostics leader with a significant U.S. installed base and comprehensive respiratory pathogen testing portfolio, while **Abbott Laboratories** stands among the largest U.S. respiratory diagnostics providers, with strong positions in rapid point-of-care and molecular testing across hospital and physician office channels. **Becton, Dickinson and Company (BD)** is a major participant in molecular diagnostics and clinical microbiology with robust respiratory infectious disease testing capabilities. Within the Danaher group, **Danaher**, through Cepheid, leads cartridge-based molecular respiratory testing with widespread adoption in hospitals, laboratories, and near-patient settings, and **Thermo Fisher Scientific** supports the market with its diagnostic reagents and instrument platforms. **Siemens Healthineers** and **Bio-Rad Laboratories** round out the competitive set as established diagnostics manufacturers with relevant infectious disease testing offerings. Differentiation hinges on assay breadth, throughput, regulatory approvals, and laboratory information system integration across immunoassay, nucleic acid amplification, and emerging biosensor-based detection formats.

• •Moderately fragmented structure: large integrated IVD manufacturers alongside smaller molecular/POC specialists
• •Technology routes span immunoassays (ELISA, lateral flow), nucleic acid amplification (PCR, isothermal), and emerging CRISPR and biosensor platforms
• •Manufacturing and R&D capacity concentrated in North American and European hubs; reagent and enzyme supply chains are global and supplier-concentrated

What are the recent trends and outlook?

The market outlook through 2033 points to sustained expansion, with continued investment in pandemic-preparedness infrastructure ensuring diagnostic capacity remains available for future respiratory threats. Multiplex panel adoption is expected to accelerate, driven by clinical demand for simultaneous detection of influenza, RSV, SARS-CoV-2, and other respiratory pathogens in a single workflow, reducing turnaround time and laboratory burden. Regulatory modernization and streamlined approval pathways for novel molecular and rapid diagnostic tests are likely to support faster time-to-market for next-generation platforms, while increasing emphasis on decentralized and home-based testing will further reshape the competitive and distribution landscape.

• •Multiplex respiratory panel adoption accelerating to enable simultaneous flu/RSV/COVID-19 detection in single workflows
• •Pandemic-preparedness infrastructure investment maintains diagnostic capacity for future emerging respiratory threats
• •Regulatory modernization and home-based testing trends will reshape distribution and competitive positioning through 2033